Bayer

Leverkusen, Germany Founded: 1863 • Age: 163 yrs Listed
Life science solutions for healthcare and agriculture are delivered.
Request Access
Report Incorrect Data
Page last updated

About Bayer

Bayer is a publicly listed company based in Leverkusen (Germany) founded in 1863 by Johann Friedrich Weskott and Friedrich Bayer. Life science solutions for healthcare and agriculture are delivered. It operates on a Direct-to-Consumer (D2C) and Professional Services model. The company has 4,350 employees. Bayer has completed 36 acquisitions, including AgraQuest, Algeta and Artificial Muscle. Its chief executive, as recorded, is Bill Anderson. Its website bayer.com draws about 1.1 million monthly visits. Bayer offers products and services including Pharmaceuticals, Crop Science, and Consumer Health. Its focus areas include Healthcare, Pharmaceuticals, Biotechnology and Crop Production. Its legal entity in India is Bayer AG (L24110MH1994PLC077013).

Company details

Bayer is established as a global enterprise with core competencies in the life sciences, focusing on healthcare and agriculture. Innovative solutions are provided to prevent, alleviate, and treat diseases in various therapeutic areas such as cardiology, oncology, and ophthalmology. In agriculture, tailored solutions are offered to farmers for planting, growing, and protecting harvests with reduced resource usage. Operations span across multiple sectors, addressing fundamental human needs through sustainable products and services. Partnerships and technological advancements are leveraged to enhance offerings in both domains.

  • Headquarters Leverkusen, Germany
  • Employees 4,350
  • Founders Johann Friedrich Weskott, Friedrich Bayer
  • Stage Public
  • Sectors
    Agriculture
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website bayer.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Bayer Ag
Operational Areas
Agriculture → Crop Inputs & Fertilizers
Key Metrics
  • Market Cap
    ₹15,612 Cr

    BAYERCROP · NSE

  • Share Price
    ₹3,448.40

    -0.73% today

  • Revenue
    ₹6,575 Cr

    FY 2025-26 · +2.8% YoY

  • EBITDA
    ₹874 Cr

    Margin 13.3%

  • Net Profit
    ₹689 Cr

    FY 2025-26 · +21.1% YoY

  • P/E (TTM)
    57.0x

    P/B 8.4x

  • ROE
    23.7%

    ROCE 28.0%

  • Debt / Equity
    0.03

    Interest cover 2.5x

  • Investors
    Gates Foundation

    & 4 more

  • Employee Count
    4,350
  • Investments & Acquisitions
    AgraQuest

    & 35 more

Products & Services of Bayer

Bayer offers a comprehensive portfolio of products and services, including Pharmaceuticals, Crop Science, and Consumer Health.

Pharmaceuticals
Healthcare

Innovative solutions for preventing and treating diseases provided.

Crop Science
Agriculture

Tailored solutions for farmers to protect harvests offered.

Consumer Health
Healthcare

Over-the-counter products for personal health are supplied.

Apps and channels of Bayer

its YouTube channel Bayer Global has 6.41K subscribers and 30 videos.

Bayer Global
YouTube 6.41K subscribers 30 videos Science & Technology
Open channel

Videos from Bayer

The most watched videos on Bayer's YouTube channel, Bayer Global (6.41K subscribers). Click a video to play it here.

Inspired By You: Anna's Story
878.7K views
Partnering with Possible: Transforming Immunology with Precision Therapies
226.2K views
Christine’s Story - Inspired By You
130.1K views
Partnering with Possible: Accelerating Discoveries in Cardiovascular Care
115.8K views

More on Bayer Global.

Funding Insights of Bayer

  • Total Rounds 25
  • First Round $597,265

    (Jul 2010)

  • Investors Count 5

Latest 10 of 25 funding rounds of Bayer with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2022Grant––
Gates Foundation
Jun 2021$61,238Grant––
European Union
May 2021$1.12MGrant––
European Union
May 2021$1.12MGrant––
European Union
Mar 2021$304,416Grant––
European Union
Feb 2021$207,894Grant––
European Union
Jan 2021$1.24MGrant––
European Union
Sep 2019Grant––
European Union
Jan 2019$77,360Grant––
European Union
Apr 2018Post-IPO––
Temasek
Valuation history

5 investors in total: 5 institutional.

Investors in Bayer

Bayer has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, HHS and Temasek.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Temasek
An investment platform is provided for diverse sectors and geographies.
1974temasek.com.sgSingapore, Singapore
Gates Foundation
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
European Union
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
HHS
Public health and human services are overseen by HHS.
1953hhs.gov
USAID
Global poverty and development are addressed through USAID initiatives.
1961usaid.gov
Premium access

Investor details for Bayer

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Bayer

766 people are tracked at Bayer (315 in leadership, 27 in board & advisors, 424 in team); the tracked headcount is 4,350.

NameRoleGroup
Johann Friedrich Weskott
Co-FounderLeadership
Friedrich Bayer
Co-FounderLeadership
Bill Anderson
CEOLeadership
Dirk Ehle
Managing DirectorLeadership
Mita T.
Director, Global Scientific Communications, CV & CGTLeadership
Shannon Hauf
Senior Vice President And Head Of North America, Australia, And New Zealand Product SupplyLeadership
Sophia Zeeden
HR Business Partner Engineering & TechnologyLeadership
Franziska Hoffmann
Executive Board Support To The CEOLeadership
Steffen Schweizer
Global Head Of Innovation ProcurementLeadership
Jacqueline De Gagné
Head of Law, Patents & Compliance & Chief Legal Officer - CanadaLeadership
Suhua Deng
Cell & Gene Therapy, Ngs/multiomics, Associate Director, Analytical DevelopmentLeadership
Keiko Tago
Director Packaging SustainabilityLeadership
Kevin Haney
Director Global Strategic Marketing - NubeqaLeadership
Alan Ambrosio
Global Product Manager Head - Data Visualization ToolsLeadership
Mikhail Rodnyanskiy
Director, R&d Regulatory Data Management, Strategy & GovernanceLeadership
Peter Godfrey
Chief Of StaffLeadership
Nikhil Gupta
Director, Prostate Marketing - Launch Team LeadLeadership
Michael Kremliovsky
Executive Director, Digital Health And Real-world Science, Science FellowLeadership
Andreas Knupp
Head Of Sales Germany - Crop ProtectionLeadership
Sara Fumagalli
Head Of OncologyLeadership

746 more people are available in the full profile.

Premium access

Complete people profiles for Bayer

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Bayer

Bayer is a publicly listed company on the NSE with ticker symbol BAYERCROP in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Jan 2010
  • Listed onNSE: BAYERCROP
  • Listed entityBayer Cropscience India Limited
  • Exchange sectorProcess industries
  • ISINDE000BAY0017
  • Share price44.66 EUR (+1.16% on the day) · 2026-10-14
  • Market capitalisation43,374,024,290.00 EUR
  • EPS (diluted, trailing year)-1.77 EUR
  • Dividend yield0.25%
  • Volume (last session)361,559

Financials of Bayer

Exchange-reported figures of Bayer Cropscience Ltd, the listed company behind Bayer (NSE: BAYERCROP).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹6,575 Cr
+2.8% YoY
EBITDA
₹874 Cr
+26.7% YoY
Profit After Tax
₹689 Cr
+21.1% YoY
Net Worth
₹2,966 Cr
+4.0% YoY
Total Assets
₹3,175 Cr
+3.6% YoY
Total Debt
₹81.80 Cr
-22.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,5756,3945,1065,1404,7344,2613,609
Revenue growth+2.8%+25.2%-0.7%+8.6%+11.1%+18.1%-
EBITDA874690957924811812596
EBITDA margin+13.3%+10.8%+18.7%+18.0%+17.1%+19.1%+16.5%
Profit before tax855707941990847794583
Net profit689569742678601486571
Net profit margin+10.5%+8.9%+14.5%+13.2%+12.7%+11.4%+15.8%
EPS (₹)153.50126.50164.92168.86143.72109.82105.68
Balance sheet
Total assets3,1753,0663,0222,9382,7282,6812,698
Net worth2,9662,8502,8492,7122,5242,5502,572
Total debt81.8010547.1073.5086.4026.301.50
Cash & bank1,4228941,1648687871,2101,071
Net working capital2,3362,2562,2802,1151,9121,9331,836
Cash flow
Cash from operations1,078262952609216687666
Cash from investing72.5085.600.4083.3064.206.70(28.90)
Cash from financing(624)(619)(656)(613)(703)(556)(148)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,2511,8351,1011,1061,5531,9151,0461,057
Revenue growth (YoY)-19.5%-4.2%+5.2%+4.6%-10.6%+17.4%--
Other income13.4088.9046.6015.9013.8018.7037.1032.20
Total expenses1,0331,4678989891,3481,5668761,037
EBITDA21836820311720534817120.20
EBITDA margin+17.4%+20.0%+18.4%+10.6%+13.2%+18.2%+16.3%+1.9%
Depreciation15.0050.1037.6014.8014.4027.2034.3015.10
Interest4.704.305.505.204.404.705.703.70
Profit before tax21140220611320033516833.60
Tax45.2080.5044.3017.3047.6056.5024.60(0.60)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,2511,8351,1011,1061,5531,9151,0461,057
Revenue growth (YoY)-19.5%-4.2%+5.2%+4.6%-10.6%+17.4%--
Other income13.4088.9046.6015.9013.8018.7037.1032.20
Total expenses1,0331,4678989891,3481,5668761,037
EBITDA21836820311720534817120.20
EBITDA margin+17.4%+20.0%+18.4%+10.6%+13.2%+18.2%+16.3%+1.9%
Depreciation15.0050.1037.6014.8014.4027.2034.3015.10
Interest4.704.305.505.204.404.705.703.70
Profit before tax21140220611320033516833.60
Tax45.2080.5044.3017.3047.6056.5024.60(0.60)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,5756,3945,1065,1404,7344,2613,609
Revenue growth+2.8%+25.2%-0.7%+8.6%+11.1%+18.1%-
Other income95.0012078.0016811368.9066.00
Total expenses5,7015,7044,1494,2163,9233,4503,013
Employee cost438450435534463362362
EBITDA874690957924811812596
EBITDA margin+13.3%+10.8%+18.7%+18.0%+17.1%+19.1%+16.5%
Depreciation94.0084.9074.0079.5064.5073.5065.30
Interest19.8017.0019.6022.3012.9012.6013.80
Profit before tax855707941990847794583
Tax166139201232202301109
Net profit689569742678601486571
Net profit margin+10.5%+8.9%+14.5%+13.2%+12.7%+11.4%+15.8%
EPS (₹)153.50126.50164.92168.86143.72109.82105.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital44.9044.9044.9044.9044.9044.9044.90
Reserves & surplus2,9212,8062,8042,6672,4792,5052,528
Shareholders' funds (net worth)2,9662,8502,8492,7122,5242,5502,572
Secured loans0.000.000.000.000.000.000.00
Unsecured loans81.8010547.1073.5086.4026.301.50
Total debt81.8010547.1073.5086.4026.301.50
Total liabilities3,1753,0663,0222,9382,7282,6812,698
Assets
Gross block929875790794743682668
Net block458470414462468425468
Capital work in progress12711911910998.3076.3055.90
Investments57.4035.4053.9041.1038.5052.2040.80
Inventories2,1362,3621,5451,8071,5121,325964
Sundry debtors1,1169529609761,005755718
Cash & bank balances1,4228941,1648687871,2101,071
Loans & advances188229182204233202221
Total current assets4,8614,4363,8523,8553,5373,4922,974
Total current liabilities2,5242,1801,5711,7401,6251,5581,138
Net working capital2,3362,2562,2802,1151,9121,9331,836
Total assets3,1753,0663,0222,9382,7282,6812,698
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash8861,1578617811,2041,067578
Net cash from operating activities1,078262952609216687666
Net cash from investing activities72.5085.600.4083.3064.206.70(28.90)
Net cash from financing activities(624)(619)(656)(613)(703)(556)(148)
Net change in cash527(272)29679.40(424)138489
Closing cash1,4228941,1648687871,2101,071
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.8%+25.2%-0.7%+8.6%+11.1%+18.1%-
EBITDA growth+26.7%-27.9%+3.6%+13.9%-0.1%+36.2%-
PBT growth+20.9%-24.9%-4.9%+16.9%+6.6%+36.3%+21.5%
Net income growth+21.1%-23.4%+9.5%+12.8%+23.7%-14.8%-
Revenue CAGR (3Y)+8.6%+10.5%+6.2%+12.5%+14.3%+16.3%+8.8%
EBITDA CAGR (3Y)-1.9%-5.3%+5.6%+15.7%+19.0%+25.6%+13.0%
Profitability & leverage
Net income margin+10.5%+8.9%+14.5%+14.8%+13.6%+11.6%+13.2%
Return on capital employed+28.0%+23.8%+32.3%+32.1%+31.8%+30.0%+28.4%
Return on net worth+23.7%+19.9%+26.6%+25.9%+25.4%+19.3%+23.7%
Debt / equity0.030.030.020.030.020.010.00
Long-term debt / equity0.020.010.010.020.010.000.00
Interest cover2.542.812.222.641.731.712.60
Efficiency & per share
Fixed asset turnover7.297.686.456.696.646.315.78
Inventory turnover2.923.273.053.103.343.723.40
Debtors turnover6.366.695.285.195.385.795.10
EPS (₹)153.50126.50164.92168.86143.72109.82105.68
Dividend per share (₹)150.00125.00140.00130.00150.00115.0025.00
Book value per share (₹)660.51634.83634.61604.03562.20568.00572.94

Investments & Acquisitions by Bayer

Bayer has strategically engaged in corporate development activities, having acquired 36 companies. Notable acquisitions include AgraQuest, Algeta and Artificial Muscle.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Perfuse Therapeutics
Developer of therapies to treat eye disorders
perfusetherapeutics.comSan Francisco, United States2018May 2026••••
Cara Care
Provider of an app for monitoring gut health
cara.careHamburg, Germany2016Dec 2024••••
FarmLead
Online marketplace for connecting grain growers and buyers
farmlead.comSaskatoon, Canada2013Jan 2023••••
Blackford Analysis
Image comparison and analysis software is provided for medical workflows.
blackfordanalysis.comEdinburgh, United Kingdom0Jan 2023••••
Targenomix
Uses systems biology approach to identify small molecules
targenomix.comPotsdam, Germany2013Nov 2022••••
CoverCress
CoverCress crop seeds are developed and supplied for agricultural use.
covercress.comSt. Louis, United States2013Aug 2022••••
Orbia Clube
Agricultural products are sold via an online marketplace platform.
orbia.agSao Paulo, Brazil2012Feb 2022••••
Vividion Therapeutics
Developing novel drugs based on a proteome-wide ligand and target discovery platform
vividion.comOceanside, United States2016Aug 2021$1.5B
AskBio
Gene and protein therapies are developed for treating various diseases.
askbio.comDurham, United States2001Oct 2020$2B
Care/of
Multi-category dietary supplements are provided via customizable subscriptions.
takecareof.comNew York, United States2016Aug 2020$225M
Premium access

Complete acquisition details for Bayer

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Bayer

14 dated milestones of Bayer across 163 years, from founding to its latest funding, stage changes and deals.

  1. Founded Bayer is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $597K.
  4. Acquisition Acquires Care/of.
  5. Acquisition Acquires AskBio.
  6. Acquisition Acquires Vividion Therapeutics.
  7. Acquisition Acquires Orbia Clube.
  8. Acquisition Acquires CoverCress.
  9. Funding Latest funding round, Grant,.
  10. Acquisition Acquires Targenomix.
  11. Acquisition Acquires Blackford Analysis.
  12. Acquisition Acquires FarmLead.
  13. Acquisition Acquires Cara Care.
  14. Acquisition Acquires Perfuse Therapeutics.

Web traffic of Bayer

The website of Bayer (bayer.com) receives about 1.1M visits a month and ranks #52,188 among all websites worldwide, #1,366 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    1.1M

    ▲ 7.3% vs previous month

  • Unique visitors
    494K

    per month

  • Global rank
    #52,188

    among all websites

  • Category rank
    #1,366

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Bayer. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Roche
roche.com
100%
1.3M#42,219View details
Novartis
novartis.com
94%
948.8K#58,822View details
Pfizer
pfizer.com
92%
1.9M#24,984View details
careers.lilly.com
careers.lilly.com
78%
#60,411–
jobs.takeda.com
jobs.takeda.com
76%
#185,912–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Bayer

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bayer

Sopris Capital Acquires Blackford Analysis to Enhance AI Orchestration in HealthTech
PR Newswire • 1 month ago
Bayer invests $2.2 billion in new US pharmaceutical plant in Ohio
FinanzNachrichten • 1 month ago
Bayer Faces Trial Test of Remaining Roundup Claims After Supreme Court Win
Insurance Journal • 1 month ago
Brazil and US Companies Collaborate on Agricultural Sustainability and Carbon Credit Projects
Grupoglobo • 1 month ago
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® elinzanetant for a New Indication
Business Wire • 1 month ago
Bayer Launches RecyClass-Certified Mono-Material Polypropylene Blister for Talcid in Germany
EuropaWire • 1 month ago
Vividion Investor Wants IP Suit Over $2B Bayer Deal Revived
Law360 • 1 month ago
Bayer to Present How it Rebuilt Global Planning with OMP at Gartner Supply Chain Planning Summit 2026
Access Newswire • 1 month ago
Bayer, Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals
Stock Screener • 1 month ago
Bayer's Monsanto Unit Urges Approval of $7.25 Billion Roundup Cancer Lawsuit Settlement
Nwaonline • 1 month ago
Premium access

Complete news archive for Bayer

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bayer

Bayer was founded in 1863 and raised its 1st funding round 147 years after it was founded.

Bayer is headquartered in Leverkusen, Germany. It is registered at Leverkusen, North Rhine-westphalia, Germany.

Bill Anderson is the CEO of Bayer, as recorded in our data.

Bayer has 4,350 employees.

Annual revenue of Bayer is $639.02M as on Mar 31, 2024.

Bayer is established as a global enterprise with core competencies in the life sciences, focusing on healthcare and agriculture. Innovative solutions are provided to prevent, alleviate, and treat diseases in various therapeutic areas such as cardiology, oncology, and ophthalmology. In agriculture, tailored solutions are offered to farmers for planting, growing, and protecting harvests with reduced resource usage. Operations span across multiple sectors, addressing fundamental human needs through sustainable products and services. Partnerships and technological advancements are leveraged to enhance offerings in both domains.

Bayer offers Pharmaceuticals, Crop Science, and Consumer Health.

Yes, Bayer is publicly traded on NSE under the ticker symbol BAYERCROP.

Bayer has made 36 acquisitions, including AgraQuest, Algeta, and Artificial Muscle.

Bayer has 5 investors. Key investors include Gates Foundation, HHS, Temasek, USAID, and European Union.

Bayer operates through Bayer Cropscience India Limited.

The website of Bayer receives about 1.1 million visits a month and ranks #52,188 among all websites worldwide.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available